B-HCG Levels in Women Diagnosed With Retained Products of Conception

Sponsor
Assaf-Harofeh Medical Center (Other)
Overall Status
Completed
CT.gov ID
NCT04917016
Collaborator
(none)
200
1
14.9
13.4

Study Details

Study Description

Brief Summary

Retained Products of Conception (RPOC) is a condition where gestational tissue remains in the uterus after birth or after a surgical or medical abortion. This condition may cause significant bleeding, infection, and long-term intrauterine adhesions associated with fertility problems and pregnancy complications (Asherman's syndrome). RPOC are diagnosed according to the clinical and ultrasound findings (such as an echogenic foci in the uterine cavity with Doppler blood flows). However, the diagnosis of RPOC by clinic and ultrasound characteristics is inaccurate and false positive results are reported in up to 40% of women undergoing a surgical procedure for RPOC removal (most often by hysterosocpy). However, surgery also carries a risk of complications and intrauterine infections. Therefore, the need arises for additional tools to improve the diagnosis available today in order to minimize the need for surgical procedures as much as possible.

The production and secretion of the B-HCG occurs in the placenta and begins after blastocyst implantation. The B-HCG levels increase in other placental pathologies such as gestational trophoblastic disease (GTD). Accordingly, the investigators hypothesized that in cases of placental remnants a secretion of B-HCG may be detected and quantified.

In this prospective, non-interventional study the investigators' aim is to examine whether B-HCG can be used as a marker for detecting placental remnants, compared to the currently accepted sonographic method. For this purpose, the investigators will examine the levels of B-HCG in participants undergoing hysteroscopy for removal of RPOC.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: Plasma B-HCG levels

Study Design

Study Type:
Observational
Actual Enrollment :
200 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
B-HCG Levels in Women Undergoing Hysteroscopy for Removal of Retained Products of Conception
Actual Study Start Date :
Dec 1, 2019
Actual Primary Completion Date :
Feb 28, 2021
Actual Study Completion Date :
Feb 28, 2021

Arms and Interventions

Arm Intervention/Treatment
Study group

Women undergoing hysteroscopy for removal of RPOC

Diagnostic Test: Plasma B-HCG levels
Blood sample

Outcome Measures

Primary Outcome Measures

  1. B-HCG levels [From randomization to the day of surgery, assessed up to 3 months]

    Plasma levels of B-HCG measured in mU/mL in women undergoing hysteroscopy for removal of RPOC

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 45 Years
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • 18 years old

  • Admitted for hysteroscopy for RPOC removal following delivery

  • Admitted for hysteroscopy for RPOC removal following abortion.

Exclusion Criteria:
  • Low suspicion of RPOC by clinical or ultrasound examination.

  • No pathology specimen available.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Shamir Medical Center Be'er Ya'aqov Israel 70200

Sponsors and Collaborators

  • Assaf-Harofeh Medical Center

Investigators

  • Principal Investigator: Noam Smorgick, MD Msc, Shamir Medical Center

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Assaf Harofeh MC, Noam Smorgick MD, Director of Minimally Invasive Gynecologic Surgery, Assaf-Harofeh Medical Center
ClinicalTrials.gov Identifier:
NCT04917016
Other Study ID Numbers:
  • 0195-19-ASF
First Posted:
Jun 8, 2021
Last Update Posted:
Jun 8, 2021
Last Verified:
Jun 1, 2021
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Assaf Harofeh MC, Noam Smorgick MD, Director of Minimally Invasive Gynecologic Surgery, Assaf-Harofeh Medical Center

Study Results

No Results Posted as of Jun 8, 2021